NCT06441955RecruitingPhase 4
Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.
Covid-19 Long Haul Syndrome: Undiagnosed Disorder Post Covid-19 Alternative Treatment Study.
Source: ClinicalTrials.gov · Last updated 27 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Investigators are conducting a study on alternative treatments for patients who have received an current or previous positive COVID-19 diagnosis with mild-serve symptoms or undiagnosable condition after testing positive for severe acute COVID-19 infection and are experiencing long-haul symptoms. The symptoms of long COVID can include extreme tiredness (fatigue), shortness of breath, memory and concentration issues (brain fog), heart palpitations, dizziness, joint pain, muscle aches, cough, headaches, anxiety, and depression. It's important to note that there are various other symptoms that individuals can experience after a COVID-19 infection, such as loss of smell, chest pain or tightness, difficulty sleeping (insomnia), pins and needles, depression, anxiety, tinnitus, earaches, nausea, diarrhea, stomach aches, loss of appetite, cough, headaches, sore throat, and changes to the sense of smell or taste. To be included in the study, participants must have had symptoms for more than 4 weeks. The goal of the study is to measure biomarkers, identify new ones through clinical trials, and individualize and optimize treatment plans, which may or may not include COVID-19 post-market antivirals, vaccines, and medical care. It's essential to conduct thorough clinical trials to understand the long-term effects of COVID-19 and to develop personalized treatment plans for individuals experiencing long-haul symptoms.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 2 Jun 2024
- Start date
- 1 Mar 2024
- Primary completion date
- 30 Sept 2030
- Lead sponsor
- Well- Konnect Healthcare Services and Research Firm
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT06441955
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 100
- From 1 Mar 2024 to the primary completion date, 30 Sept 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Medical History of Myocarditis
- Medical History of Pericarditis
Lab values
- Medical History of Severe renal impairment (eGFR \<30 mL/min).
Age
- \>18 years of age
Who the study is looking for
- Inclusion of Men, Women, and Minorities
- Participants must be at least 18 years old.
- Participants must have a positive COVID-19 diagnosis or clinical diagnosis of COVID-19
- Participants must have experienced persistent symptoms after recovering from the acute phase of the illness.
- Participants must be willing to provide informed consent to participate in the study.
- Participants must be able to communicate effectively in English or have a translator available.
- Participants must be able to attend follow-up appointments as required by the study protocol.
- Participants must not have any medical conditions or take any medications that could interfere with the study results.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NIH Clinical Center Coordinator of this site? Confirm its status | Bethesda | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.